drugset / Trial / NCT00062894

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

NCT00062894

Phase 1/2 Completed 12 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who have received a dosimetric dose of fission-derived iodine I 131 tositumomab.

Timeline

Start
2003-04
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TOSITUMOMAB 131I Monoclonal antibody

Indications